Neurodegenerative Drugs Market By Drug Class (Dopamine agonist , Decarboxylase inhibitors , Cholinesterase Inhibitors , Immunomodulators, Others ), By Indication (Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis , Others), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
The neurodegenerative drugs market valued for $36,277.20 million in 2021 and is estimated to reach $74,809.38 million by 2031, exhibiting a CAGR of 7.5% from 2022 to 2031. Neurodegenerative diseases refer to a group of disorders that primarily affect the neurons (nerve cells) in the brain and spinal cord, leading to their gradual degeneration. These diseases are usually progressive and chronic, and their symptoms worsen over time. Examples of neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). These conditions have a significant impact on a person's cognitive, motor, & sensory functions, and can ultimately lead to disability and death.
Drugs used to treat neurodegenerative diseases are medications that are designed to slow down the progression of the disease and/or relieve symptoms. The specific drugs used will depend on the type of neurodegenerative disease being treated. For example, drugs used to treat Alzheimer's disease include cholinesterase inhibitors and memantine, while drugs used to treat Parkinson's disease include levodopa, dopamine agonists, and MAO-B inhibitors.
The major factor that drives the growth of the global neurodegenerative drugs market is rise in demand for advanced drug types for controlling symptoms associated with neurodegenerative diseases. In addition, a strong pipeline for neurodegenerative disease is a key trend in the market, which is expected to fuel the growth of the market. Significant surge in patient population has led to increase in demand for drugs. However, complications associated with drug development process and side effects of drugs are expected to hamper the market growth.
On the other hand, high growth potential in untapped emerging countries, increase in pipeline products such as BAF312 & Orelabrutinib for treating multiple sclerosis disease, and continuous drug approval of neurodegenerative diseases are anticipated to provide lucrative opportunities to the market players. For instance, in January 2020, Novartis AG announced that the European Commission (EC) has approved Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
The neurodegenerative drugs market is segmented into drug class, indication, distribution channel, and region. By drug class, the market is categorized into dopamine agonists, decarboxylase inhibitors, cholinesterase inhibitors, immunomodulators, and others. By indication, the market is segregated into Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and others. By distribution channel, the market is classified into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global neurodegenerative drugs market are AbbVie Inc., Biogen, F. Hoffmann-La Roche Ltd., Novartis AG, Orion Corporation, Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and UCB S.A. Key players operating in the market have adopted product approval, acquisition, collaboration, and agreement as their key strategies to expand their corporate training market share.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neurodegenerative drugs market analysis from 2021 to 2031 to identify the prevailing neurodegenerative drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the neurodegenerative drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global neurodegenerative drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
Dopamine agonist
Decarboxylase inhibitors
Cholinesterase Inhibitors
Immunomodulators
Others
By Indication
Parkinson’s Disease
Alzheimer’s Disease
Multiple Sclerosis
Others
By Distribution Channel
Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Orion Corporation
Biogen
Sanofi
Viatris Inc.
Novartis AG
UCB S.A.
AbbVie Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in prevalence of neurodegenerative diseases
- 3.4.1.2. Initiatives by government and non-government organizations
- 3.4.1.3. Expected launch of new drugs during the forecast period
- 3.4.2. Restraints
- 3.4.2.1. Complications associated with drug development
- 3.4.3. Opportunities
- 3.4.3.1. Increase in R&D activities
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Dopamine agonist
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Decarboxylase inhibitors
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Cholinesterase Inhibitors
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Immunomodulators
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- 4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
- CHAPTER 5: NEURODEGENERATIVE DRUGS MARKET, BY INDICATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Parkinson’s Disease
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Alzheimer’s Disease
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Multiple Sclerosis
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- 5.5. Others
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
- CHAPTER 6: NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Online Providers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Drug Stores and Retail Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: NEURODEGENERATIVE DRUGS MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drug Class
- 7.2.3. Market size and forecast, by Indication
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Drug Class
- 7.2.5.1.3. Market size and forecast, by Indication
- 7.2.5.1.4. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Drug Class
- 7.2.5.2.3. Market size and forecast, by Indication
- 7.2.5.2.4. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Drug Class
- 7.2.5.3.3. Market size and forecast, by Indication
- 7.2.5.3.4. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drug Class
- 7.3.3. Market size and forecast, by Indication
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Drug Class
- 7.3.5.1.3. Market size and forecast, by Indication
- 7.3.5.1.4. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Drug Class
- 7.3.5.2.3. Market size and forecast, by Indication
- 7.3.5.2.4. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Drug Class
- 7.3.5.3.3. Market size and forecast, by Indication
- 7.3.5.3.4. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Drug Class
- 7.3.5.4.3. Market size and forecast, by Indication
- 7.3.5.4.4. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Drug Class
- 7.3.5.5.3. Market size and forecast, by Indication
- 7.3.5.5.4. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Drug Class
- 7.3.5.6.3. Market size and forecast, by Indication
- 7.3.5.6.4. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drug Class
- 7.4.3. Market size and forecast, by Indication
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Drug Class
- 7.4.5.1.3. Market size and forecast, by Indication
- 7.4.5.1.4. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Drug Class
- 7.4.5.2.3. Market size and forecast, by Indication
- 7.4.5.2.4. Market size and forecast, by Distribution Channel
- 7.4.5.3. Australia
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Drug Class
- 7.4.5.3.3. Market size and forecast, by Indication
- 7.4.5.3.4. Market size and forecast, by Distribution Channel
- 7.4.5.4. India
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Drug Class
- 7.4.5.4.3. Market size and forecast, by Indication
- 7.4.5.4.4. Market size and forecast, by Distribution Channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Drug Class
- 7.4.5.5.3. Market size and forecast, by Indication
- 7.4.5.5.4. Market size and forecast, by Distribution Channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Drug Class
- 7.4.5.6.3. Market size and forecast, by Indication
- 7.4.5.6.4. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drug Class
- 7.5.3. Market size and forecast, by Indication
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Drug Class
- 7.5.5.1.3. Market size and forecast, by Indication
- 7.5.5.1.4. Market size and forecast, by Distribution Channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Drug Class
- 7.5.5.2.3. Market size and forecast, by Indication
- 7.5.5.2.4. Market size and forecast, by Distribution Channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Drug Class
- 7.5.5.3.3. Market size and forecast, by Indication
- 7.5.5.3.4. Market size and forecast, by Distribution Channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Drug Class
- 7.5.5.4.3. Market size and forecast, by Indication
- 7.5.5.4.4. Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2021
- CHAPTER 9: COMPANY PROFILES
- 9.1. Novartis AG
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. AbbVie Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. F. Hoffmann-La Roche Ltd.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. Teva Pharmaceutical Industries Ltd.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Sanofi
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. Orion Corporation
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Sun Pharmaceutical Industries Ltd.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. UCB S.A.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Viatris Inc.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. Biogen
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 02. NEURODEGENERATIVE DRUGS MARKET FOR DOPAMINE AGONIST , BY REGION, 2021-2031 ($MILLION)
- TABLE 03. NEURODEGENERATIVE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS , BY REGION, 2021-2031 ($MILLION)
- TABLE 04. NEURODEGENERATIVE DRUGS MARKET FOR CHOLINESTERASE INHIBITORS , BY REGION, 2021-2031 ($MILLION)
- TABLE 05. NEURODEGENERATIVE DRUGS MARKET FOR IMMUNOMODULATORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 06. NEURODEGENERATIVE DRUGS MARKET FOR OTHERS , BY REGION, 2021-2031 ($MILLION)
- TABLE 07. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 08. NEURODEGENERATIVE DRUGS MARKET FOR PARKINSON’S DISEASE, BY REGION, 2021-2031 ($MILLION)
- TABLE 09. NEURODEGENERATIVE DRUGS MARKET FOR ALZHEIMER’S DISEASE, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. NEURODEGENERATIVE DRUGS MARKET FOR MULTIPLE SCLEROSIS , BY REGION, 2021-2031 ($MILLION)
- TABLE 11. NEURODEGENERATIVE DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 13. NEURODEGENERATIVE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. NEURODEGENERATIVE DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 15. NEURODEGENERATIVE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. NEURODEGENERATIVE DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 17. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 18. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 19. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 20. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. U.S. NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 22. U.S. NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 23. U.S. NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 24. CANADA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 25. CANADA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 26. CANADA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 27. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 28. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 29. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 30. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 31. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 32. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 33. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 34. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 35. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 36. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 37. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 38. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 39. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 40. UK NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 41. UK NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 42. UK NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 43. ITALY NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 44. ITALY NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 45. ITALY NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 46. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 47. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 48. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 49. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 50. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 51. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 52. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 53. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 54. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 55. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 56. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 57. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 58. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 59. CHINA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 60. CHINA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 61. CHINA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 62. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 63. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 64. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 65. INDIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 66. INDIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 67. INDIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 68. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 69. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 70. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 71. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 72. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 73. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 74. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 75. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 76. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 77. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 78. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 79. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 80. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 81. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 82. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 83. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 84. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 85. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 86. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 87. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 88. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 89. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 90. NOVARTIS AG: KEY EXECUTIVES
- TABLE 91. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 92. NOVARTIS AG: PRODUCT SEGMENTS
- TABLE 93. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 94. NOVARTIS AG: KEY STRATERGIES
- TABLE 95. ABBVIE INC.: KEY EXECUTIVES
- TABLE 96. ABBVIE INC.: COMPANY SNAPSHOT
- TABLE 97. ABBVIE INC.: PRODUCT SEGMENTS
- TABLE 98. ABBVIE INC.: PRODUCT PORTFOLIO
- TABLE 99. ABBVIE INC.: KEY STRATERGIES
- TABLE 100. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 101. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 102. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
- TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 106. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 107. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 108. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
- TABLE 109. SANOFI: KEY EXECUTIVES
- TABLE 110. SANOFI: COMPANY SNAPSHOT
- TABLE 111. SANOFI: PRODUCT SEGMENTS
- TABLE 112. SANOFI: PRODUCT PORTFOLIO
- TABLE 113. ORION CORPORATION: KEY EXECUTIVES
- TABLE 114. ORION CORPORATION: COMPANY SNAPSHOT
- TABLE 115. ORION CORPORATION: PRODUCT SEGMENTS
- TABLE 116. ORION CORPORATION: PRODUCT PORTFOLIO
- TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 121. UCB S.A.: KEY EXECUTIVES
- TABLE 122. UCB S.A.: COMPANY SNAPSHOT
- TABLE 123. UCB S.A.: PRODUCT SEGMENTS
- TABLE 124. UCB S.A.: PRODUCT PORTFOLIO
- TABLE 125. UCB S.A.: KEY STRATERGIES
- TABLE 126. VIATRIS INC.: KEY EXECUTIVES
- TABLE 127. VIATRIS INC.: COMPANY SNAPSHOT
- TABLE 128. VIATRIS INC.: PRODUCT SEGMENTS
- TABLE 129. VIATRIS INC.: PRODUCT PORTFOLIO
- TABLE 130. BIOGEN: KEY EXECUTIVES
- TABLE 131. BIOGEN: COMPANY SNAPSHOT
- TABLE 132. BIOGEN: PRODUCT SEGMENTS
- TABLE 133. BIOGEN: PRODUCT PORTFOLIO
- TABLE 134. BIOGEN: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. NEURODEGENERATIVE DRUGS MARKET, 2021-2031
- FIGURE 02. SEGMENTATION OF NEURODEGENERATIVE DRUGS MARKET, 2021-2031
- FIGURE 03. TOP INVESTMENT POCKETS IN NEURODEGENERATIVE DRUGS MARKET (2022-2031)
- FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
- FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 06. LOW THREAT OF SUBSTITUTES
- FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 08. MODERATE INTENSITY OF RIVALRY
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALNEURODEGENERATIVE DRUGS MARKET
- FIGURE 10. NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DOPAMINE AGONIST , BY COUNTRY 2021 AND 2031(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS , BY COUNTRY 2021 AND 2031(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR CHOLINESTERASE INHIBITORS , BY COUNTRY 2021 AND 2031(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR IMMUNOMODULATORS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR OTHERS , BY COUNTRY 2021 AND 2031(%)
- FIGURE 16. NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY 2021 AND 2031(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY 2021 AND 2031(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR MULTIPLE SCLEROSIS , BY COUNTRY 2021 AND 2031(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 21. NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
- FIGURE 22. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
- FIGURE 23. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021 AND 2031(%)
- FIGURE 24. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
- FIGURE 25. NEURODEGENERATIVE DRUGS MARKET BY REGION, 2021
- FIGURE 26. U.S. NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 27. CANADA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 28. MEXICO NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 29. GERMANY NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 30. FRANCE NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 31. UK NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 32. ITALY NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 33. SPAIN NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 34. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 35. JAPAN NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 36. CHINA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 37. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 38. INDIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 39. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 40. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 41. BRAZIL NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 42. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 43. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 44. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
- FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 49. COMPETITIVE DASHBOARD
- FIGURE 50. COMPETITIVE HEATMAP: NEURODEGENERATIVE DRUGS MARKET
- FIGURE 51. TOP PLAYER POSITIONING, 2021
- FIGURE 52. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 53. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 54. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 55. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 56. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 57. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 58. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 59. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 60. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 63. SANOFI: NET SALES, 2020-2022 ($MILLION)
- FIGURE 64. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 65. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 66. ORION CORPORATION: NET SALES, 2020-2022 ($MILLION)
- FIGURE 67. ORION CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 68. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 69. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 70. UCB S.A.: NET SALES, 2020-2022 ($MILLION)
- FIGURE 71. UCB S.A.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 72. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
- FIGURE 73. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 74. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 75. BIOGEN: REVENUE SHARE BY REGION, 2021 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook